Overuse and Underuse of Antiosteoporotic Treatments According to Highly Influential Osteoporosis Guidelines: A Population-Based Cross-Sectional Study in Spain

PloS One
Gabriel Sanfélix-GimenoSalvador Peiró

Abstract

Inappropriate prescribing of antiosteoporotic medications has been observed; however, the joint study of both overuse and underuse has barely been attempted. Spain, with its high utilization rates, constitutes a good example to assess differences in over and under use according to diverse highly-influential osteoporosis guidelines (HIOG) worldwide. We used data of a population-based cross-sectional study including 824 post-menopausal women ≥50 years old living in the city of Valencia, Spain and aimed to estimate the percentage of women eligible for treatment, and the proportion of overuse and underuse of antiosteoporotic treatment according to HIOG. The prevalence of antiosteoporotic treatment in postmenopausal women ≥ 50 in Valencia was 20.9% (95%CI:17.6-24.4). The type of antiosteoporotic drugs prescribed varied greatly depending on the medical specialty responsible of the initial prescription. When applying the HIOG, the percentage of women 50 and over who should be treated varied from less than 9% to over 44%. In real terms, from the approximately eight million women of 50 years old and over in Spain, the number eligible for treatment would range from 0.7 to 3.8 million, depending on the guideline used. A huge proportion of...Continue Reading

References

Jul 1, 1986·American Journal of Public Health·R E ParkD H Solomon
Sep 1, 1993·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·H K GenantM C Nevitt
Sep 28, 1998·JAMA : the Journal of the American Medical Association·M R Chassin, R W Galvin
Jul 19, 2002·JAMA : the Journal of the American Medical Association·Jacques E RossouwUNKNOWN Writing Group for the Women's Health Initiative Investigators
May 6, 2003·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·M NavesJ B Cannata-Andía
Sep 25, 2003·Archives of Internal Medicine·Susan E AndradeJerry H Gurwitz
Aug 11, 2005·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·M NavesJorge B Cannata-Andía
Feb 23, 2008·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·J A KanisE McCloskey
Jan 27, 2009·Health Services Research·Salomeh Keyhani, Albert L Siu
Feb 12, 2010·The Journal of Clinical Endocrinology and Metabolism·Mark J Bolland, Andrew Grey
Oct 14, 2010·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Alexandra PapaioannouUNKNOWN Scientific Advisory Council of Osteoporosis Canada
Apr 8, 2011·Health and Quality of Life Outcomes·José Sanfélix-GenovésSalvador Peiró
Apr 9, 2011·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·W D LeslieL M Lix
Nov 15, 2011·Reumatología clinica·Lluís Pérez EdoUNKNOWN Spanish Society of Rheumatology
Dec 16, 2011·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·J Sanfélix-GenovésM Vega-Martínez
Jan 25, 2012·Archives of Internal Medicine·Deborah KorensteinSalomeh Keyhani
Mar 16, 2012·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·J A KanisUNKNOWN IOF Working Group on Epidemiology and Quality of Life
May 24, 2012·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·J Sanfélix-GenovésC Baixauli
Jun 22, 2012·Primary Health Care Research & Development·Li WangRoss E G Upshur
Oct 12, 2012·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·J D Pedrera-ZamoranoJ M Moran
Nov 6, 2012·Maturitas·M Esther SalgueiroDolors Capellà
Dec 26, 2012·JAMA Internal Medicine·Minal S KaleSalomeh Keyhani
Feb 15, 2013·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·F Catalá-LópezS Peiró
Mar 27, 2013·JAMA Internal Medicine·Derek J EmeryThomas E Feasby
May 29, 2013·JAMA Internal Medicine·Allison Lipitz-Snyderman, Peter B Bach
Jun 28, 2013·Medical Care Research and Review : MCRR·Kitty S ChanJodi B Segal
Nov 14, 2013·Journal of the American Geriatrics Society·Stephen K LiuNancy E Morden
Jan 5, 2014·The Journal of Clinical Endocrinology and Metabolism·Isabel HurtadoJosé Sanfélix-Genovés

❮ Previous
Next ❯

Methods Mentioned

BETA
hormone replacement therapy

Software Mentioned

STATA

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.